Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Amylin receptors (AMYRs), heterodimers of the calcitonin receptor (CTR) and one of three receptor activity-modifying proteins, are promising obesity targets. A hallmark of AMYR activation by Amy is the formation of a 'bypass' secondary structural motif (residues S19-P25). This study explored potential tuning of peptide selectivity through modification to residues 19-22, resulting in a selective AMYR agonist, San385, as well as nonselective dual amylin and calcitonin receptor agonists (DACRAs), with San45 being an exemplar. We determined the structure and dynamics of San385-bound AMYR, and San45 bound to AMYR or CTR. San45, via its conjugated lipid at position 21, was anchored at the edge of the receptor bundle, enabling a stable, alternative binding mode when bound to the CTR, in addition to the bypass mode of binding to AMYR. Targeted lipid modification may provide a single intervention strategy for design of long-acting, nonselective, Amy-based DACRAs with potential anti-obesity effects.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41589-023-01393-4DOI Listing

Publication Analysis

Top Keywords

calcitonin receptor
12
amylin calcitonin
8
receptor agonists
8
receptor
5
amyr
5
structural insight
4
insight selectivity
4
selectivity amylin
4
agonists amylin
4
amylin receptors
4

Similar Publications

Perineural botulinum toxin in the management of post-traumatic headache: a case report.

Rev Esp Anestesiol Reanim (Engl Ed)

September 2025

Physical Medicine and Rehabilitation. Universidad del Valle, Cali, Colombia; Interventional Pain Management, Fundalivio, Cali, Colombia.

Post traumatic headache is a common condition that can be managed with pharmacologic interventions or analgesic procedures; however, most evidence is derived from patients with mild trauma, leaving a large gap with regard to patients with moderate or severe trauma who present complex pain. Botulinum toxin plays an increasingly important role in pain management. This neurotoxin acts on different receptors, ranging from TRPV1 (transient receptor potential vanilloid type 1) to CGRP (calcitonin gene-related peptide).

View Article and Find Full Text PDF

A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use.

Endocrinol Diabetes Metab Case Rep

July 2025

Department of Internal Medicine, Medical City Arlington, Arlington, Texas, USA.

Summary: Hypercalcemia is a prevalent electrolyte disturbance commonly associated with primary hyperparathyroidism, cancer, or medication adverse effects. Thiazide diuretics reduce urinary calcium excretion, increasing calcium reabsorption and hypercalcemia. Tirzepatide, a dual GIP and GLP-1 receptor agonist, is increasingly used for type 2 diabetes and obesity.

View Article and Find Full Text PDF

A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy.

Curr Drug Targets

August 2025

Department of Medicinal Biotechnology, College of Health Science, Dong-A University, Busan, 49315, Republic of Korea.

Amylin is a thirty-seven amino acid peptide hormone that is secreted from the pancreas with insulin. The peptide hormone amylin activates its receptors in the brain to regulate blood glucose and food appetite. Interestingly, the amylin receptor is the heterodimer of the calcitonin receptor (which is the receptor for the peptide hormone calcitonin) and an accessory protein called receptor activity-modifying protein.

View Article and Find Full Text PDF

The interest in dry needling as a treatment option for myofascial pain has flourished for the last decades and will probably continue to do so, since multiple clinical effects can be attributed to this technique. However, evidence about the underlying physiological mechanisms of its effects is still underrepresented in scientific research and caution must be taken in generalizing results from acupuncture or animal research. This review offers an overview of the possible mechanisms involved in the pathophysiology of myofascial trigger points, i.

View Article and Find Full Text PDF

Background: Atogepant is a CGRP receptor antagonist used in prevention of migraine. This study assesses the safety and efficacy of this drug in management of migraine headaches.

Methods: PubMed, Scopus, Web of Science, and Cochrane CENTRAL were searched until March 24, 2025.

View Article and Find Full Text PDF